# US 2024/0199593 A1 · Novel Heteroaryl Aminopropanol Derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199593 A1
- Document ID: US20240199593A1
- Status: Published application
- Kind: A1
- Application number: 18/426,461
- Filed: 2024-01-30
- Published: 2024-06-20
- Earliest claimed: 2021-04-16
- Assignees: Novartis AG
- Applicants: Novartis AG
- Inventors: Andreas Kordikowski; Yugang Liu; Rainer Martin Lüönd; Christian Markert; Wolfgang Miltz; Till Roehn; Carsten Spanka; Gebhard Thoma; Tian XIE
- Web page: https://patentgrep.com/patent/US20240199593A1

## CPC

- C07D 413/10: linked by a carbon chain containing aromatic rings
- A61K 31/41: having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K 31/4245: Oxadiazoles
- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 17/00: Drugs for dermatological disorders
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- C07D 257/04: Five-membered rings
- C07D 271/06: 1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 413/14: containing three or more hetero rings
- C07D 471/04: Ortho-condensed systems
- C07D 491/056: with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a crystalline form of (S)-2-amino-3-(3-(4-((3-fluoro-5-(1H-pyrazol-5-yl)pyridin-2-yl)oxy)phenyl)-1H-pyrazol-1-yl)propan-1-ol, in its free form; a method for manufacturing said crystalline form, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

## Claims

### Claim 1

A crystalline form of (S)-2-amino-3-(3-(4-((3-fluoro-5-(1H-pyrazol-5-yl)pyridin-2-yl)oxy)phenyl)-1H-pyrazol-1-yl)propan-1-ol, in its free form.

### Claim 2 (depends on 1)

The crystalline form C according to claim 1, characterized by an x-ray powder diffraction pattern comprising four or more 2 s values selected from the group consisting of 11.4±0.2° 2θ, 15.2±0.2° 2θ, 15.9±0.2° 2θ, 16.9±0.2° 2θ, 18.3±0.2° 2θ, 22.8±0.2° 2θ, 24.6±0.2° 2θ, and 28.6±0.2° 2θ, measured at a temperature of about 25° C. and an x-ray wavelength, λ, of 1.5406 Å.

### Claim 3 (depends on 2)

The crystalline form C according to claim 2, characterized by an x-ray powder diffraction pattern comprising five or more 20 values selected from the group consisting of 11.4±0.2° 2θ, 15.2±0.2° 2θ, 15.9±0.2° 2θ, 16.9±0.2° 2θ, 18.3±0.2° 2θ, 22.8±0.2° 2θ, 24.6±0.2° 2θ, and 28.6±0.2° 2θ, measured at a temperature of about 25° C. and an x-ray wavelength, λ, of 1.5406 Å

### Claim 4 (depends on 2)

The crystalline form C according to claim 2, characterized by an x-ray powder diffraction pattern comprising representative peaks in terms of 20 at 11.4±0.2° 2θ, 15.2±0.2° 2θ, 22.8±0.2° 2θ and 28.6±0.2° 2θ, measured at a temperature of about 25° C. and an x-ray wavelength, λ, of 1.5406 Å.

### Claim 5 (depends on 2)

The crystalline form C according to claim 2, characterized by an x-ray powder diffraction pattern comprising four or more 20 values selected from the group consisting of 11.4±0.2° 2θ, 15.2±0.2° 2θ, 15.9±0.2° 2θ, 16.9±0.2° 2θ, 18.3±0.2° 2θ, 22.8±0.2° 2θ, 24.6±0.2° 2θ, and 28.6±0.2° 2θ, measured at a temperature of about 25° C. and an x-ray wavelength, λ, of 1.5406 Å.

### Claim 6 (depends on 2)

The crystalline form C according to claim 2, having an x-ray powder diffraction substantially the same as that shown in FIG. 1a.

### Claim 7 (depends on 2)

The crystalline form C according to claim 2, having a differential scanning calorimetry (DSC) substantially the same as that shown in FIG. 1b.

### Claim 8 (depends on 2)

The crystalline form C according to claim 2, having a thermogravimetric analysis (TGA) diagram substantially the same as that shown in FIG. 1c.

### Claim 9 (depends on 1)

The crystalline form D according to claim 1, characterized by an x-ray powder diffraction pattern comprising four or more 20 values selected from the group consisting of 11.3±0.2° 2θ, 15.2±0.2° 2θ, 18.3±0.2° 2θ, 19.2±0.2° 2θ, 20.3±0.2° 2θ, 21.6±0.2° 2θ, 22.8±0.2° 2θ, 24.2±0.2° 2θ and 28.6±0.2° 2θ, measured at a temperature of about 25° C. and an x-ray wavelength, λ, of 1.5406 Å.

### Claim 10 (depends on 9)

The crystalline form D according to claim 9, characterized by an x-ray powder diffraction pattern comprising five or more 20 values selected from the group consisting of 11.3±0.2° 2θ, 15.2±0.2° 2θ, 18.3±0.2° 2θ, 19.2±0.2° 2θ, 20.3±0.2° 2θ, 21.6±0.2° 2θ, 22.8±0.2° 2θ, 24.2±0.2° 2θ and 28.6±0.2° 2θ, measured at a temperature of about 25° C. and an x-ray wavelength, λ, of 1.5406 Å;

### Claim 11 (depends on 9)

The crystalline form D according to claim 9, characterized by an x-ray powder diffraction pattern comprising representative peaks in terms of 20 at 11.3±0.2° 2θ, 18.3±0.2° 2θ, 24.2±0.2° 2θ and 28.6±0.2° 2θ, measured at a temperature of about 25° C. and an x-ray wavelength, λ, of 1.5406 Å;

### Claim 12 (depends on 9)

The crystalline form D according to claim 9, characterized by an x-ray diffraction spectrum substantially the same as the x-ray powder diffraction spectrum shown in FIG. 2A.

### Claim 13 (depends on 9)

The crystalline form D according to claim 9, characterized by a differential scanning calorimetry (DSC) thermogram substantially the same as that shown in shown in FIG. 2B.

### Claim 14 (depends on 9)

The crystalline form D according to claim 9, characterized by a thermo gravimetric analysis (TGA) diagram substantially the same as that shown in shown in FIG. 2C.

### Claim 15 (depends on 1)

A pharmaceutical composition comprising a crystalline form according to claim 1; and one or more pharmaceutically acceptable carriers.

### Claim 16 (depends on 1)

A combination comprising a therapeutically effective amount of a compound according to any one of claim 1 and one or more therapeutically active co-agents.

### Claim 17 (depends on 1)

A method of treatment of a disease and/or disorder mediated by LTA4H activity in a subject, wherein the method comprises administering to said subject a therapeutically effective amount of the crystalline form according to claim 1.

### Claim 18 (depends on 17)

The method of treatment according to claim 17 wherein the disease and/or disorder is selected from: acute or chronic inflammation, anaphylactic reactions, allergic reactions, atopic dermatitis, psoriasis, acute respiratory distress syndrome, immune complex-mediated pulmonary injury and chronic obstructive pulmonary disease, inflammatory bowel diseases (including ulcerative colitis, Crohn's disease and post-surgical trauma), gastrointestinal ulcers, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), neutrophilic dermatoses (including but not limited to Pyoderma gangrenosum, Sweet's syndrome, acne and neutrophilic urticaria), immune-complex-mediated glomerulonephritis, Hidradenitis suppurativa, autoimmune diseases (including insulin-dependent diabetes mellitus, multiple sclerosis, rheumatoid arthritis, osteoarthritis and systemic lupus erythematosus), vasculitides (including but not limited to cutaneous vasculitis, Behcets disease and Henoch Schönlein Purpura), cardiovascular disorders (including, but not limited to hypertension, atherosclerosis, aneurysm, critical leg ischemia, peripheral arterial occlusive disease, pulmonary artery hypertension and Reynaud's syndrome), sepsis, inflammatory and neuropathic pain including arthritic pain, periodontal disease including gingivitis, ear infections, migraine, benign prostatic hyperplasia, Sjogren-Larsson Syndrome and cancers (including, but not limited to, leukemias and lymphomas, prostate cancer, breast cancer, lung cancer, malignant melanoma, renal carcinoma, head and neck tumors and colorectal cancer).
